ALLO-647 + Fludarabine + Cyclophosphamide
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Trial Timeline
Feb 24, 2021 → Dec 1, 2025
NCT ID
NCT04696731About ALLO-647 + Fludarabine + Cyclophosphamide
ALLO-647 + Fludarabine + Cyclophosphamide is a phase 1 stage product being developed by Allogene Therapeutics for Advanced/Metastatic Clear Cell Renal Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04696731. Target conditions include Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Clear Cell Renal Cell Carcinoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05714345 | Phase 2 | Terminated |
| NCT05000450 | Phase 1/2 | Terminated |
| NCT04696731 | Phase 1 | Active |
| NCT04416984 | Phase 1/2 | Active |
| NCT03939026 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced/Metastatic Clear Cell Renal Cell Carcinoma